ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
- Myeloproliferative Neoplasm (MDS/MPN)
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04639024
- Collaborators
- ADC Therapeutics S.A.
- Investigators
- Principal Investigator: David Rizzieri Professor of Medicine, Hematologic Malignancies & Cell Therapy